Retrophin, Inc. (RTRX)
(Delayed Data from NSDQ)
$19.72 USD
+0.61 (3.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.75 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
Travere Therapeutics, Inc. [RTRX]
Reports for Purchase
Showing records 1 - 20 ( 35 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 75.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Commercial Execution, Catalysts Ahead - Much To Like For RTRX In 3Q20 Report
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Price: 25.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 50.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 75.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney KOL Call Takeaways: Double The Fun - Closer Look At Sparsentan, FSGS
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Price: 25.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PROTECTing The Readout Timing - PROTECT Study Reaches Interim Enrollment Target
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with an Outperform rating and $33 target
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Price: 100.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dial In to Part 1 of Our FSGS Expert Call Series Today at 11am ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of Retrophin, Inc -as we are focusing our efforts elsewhere in the biotechnology sector
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Further Thiola Details to Drive Revenue Growth; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Further Pipeline and Revenue Build Bolstering Company Strategy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q14 Results; RE-024 Dosing Set to Begin This Week; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PKAN Moves Forward; Tweaking Projections; Off Focus List; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00